Sebastian H.
- Country
- Germany
- Department
- Klinik u. Poliklinik für Dermatologie
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Evaluation of Diclofenac in Combination with PD-1 Inhibitors Nivolumab or Pembrolizumab in Metastatic Melanoma with Stable Disease Response
- Phase II Evaluation of Intratumoral L19IL2 and L19TNF in High-Risk Locally Advanced Basal Cell and Cutaneous Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 35 of 134 partner sites.
Specializations
Melanoma Research
The investigator specializes in the treatment of advanced melanoma, with particular focus on metastatic and unresectable cases. Their research encompasses both locally advanced melanoma and stage IIB/C melanoma management.
- BRAF V600E/K mutation-positive melanoma treatment
- Neoadjuvant therapy approaches
- Post-surgical recurrence prevention
The investigator explores innovative combination therapies including targeted treatments and immunotherapy agents.
Skin Cancer Studies
Research activities extend to non-melanoma skin cancers, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). Special attention is given to high-risk and locally advanced cases.
- Intratumoral injection therapies
- Alternative treatments for surgery-ineligible patients
- Novel therapeutic approaches for advanced skin cancers
Focus includes developing treatment options for patients unsuitable for conventional surgery or radiation therapy.
Immunotherapy Innovation
The investigator leads research in immune checkpoint inhibition and related therapeutic approaches. Their work includes managing immune-related adverse events and developing novel treatment combinations.
- PD-1 inhibitor therapies
- Combination immunotherapy protocols
- Extracorporeal photopheresis treatments
Research encompasses both primary treatments and strategies for addressing therapy resistance.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.